Bloomberg |
Merck Pauses Enrolling Blood Cancer Studies, Cites Deaths
Bloomberg Merck & Co. is pausing enrollment of two studies of its Keytruda cancer immunotherapy treatment in patients with a form of blood cancer, following reports of deaths among those taking the drug. Patients with multiple myeloma who are already enrolled in ... After-hours buzz: MRK, XLRN & more Merck halts enrollment on two PhIII Keytruda combo studies as outside monitors flag a worrying rate of deaths Merck (MRK) Presents Update on Multiple Myeloma Studies KEYNOTE-183 & 185 of KEYTRUDA (pembrolizumab) in ... |
from Health - Google News http://ift.tt/2rcbuTz
EmoticonEmoticon